The ISSCR’s VISION2030 gathers global leaders in stem cell research and regenerative medicine

0

Biotech business innovators and scientific trailblazers converge for a must attend future-forward event 7-8 January 2021

Skokie, IL – The ISSCR’s VISION2030 is bringing together biotech CEOs who have successfully transformed scientific breakthroughs into thriving businesses that are improving human health. Join us for in-depth executive interviews that explore the next decade for the field on 7-8 January 2021. The event comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect. Register and see the full program.

Thursday, 7 January

12:00 to 17:30 EST

12:00 EST

Welcome Remarks

  • Christine L. Mummery, ISSCR President / Leiden University Medical Center, Netherlands
  • Deepak Srivastava, Gladstone Institute/UCSF, USA l ISSCR Immediate Past President
  • Leonard I. Zon, Boston Children’s Hospital, USA l ISSCR Founder

12:15 EST

BlueRock Therapeutics Executive Interview

  • Emile Nuwaysir, President and Chief Executive Officer, BlueRock Therapeutics, USA
  • Lorenz Studer, Founding Scientist, BlueRock Therapeutics l Sloan Kettering Institute for Cancer Research, USA
  • Viviane Tabar, Founding Scientist, BlueRock Therapeutics l Memorial Sloan Kettering Center, USA

Interviewed by ISSCR Board Member Arnold R. Kriegstein, University of California, San Francisco, USA

BlueRock Therapeutics is advancing their novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

12:45 EST

Surrozen Executive Interview

  • Craig Parker, Chief Executive Officer, Surrozen, USA
  • Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder

Interviewed by ISSCR Past President Hans C. Clevers, Hubrecht Institute, Netherlands l Surrozen Founder

Surrozen is pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and restore organs damaged by serious disease.

13:25 EST

ElevateBio Executive Interview

  • Mitchell H. Finer, Scientific Founder and Chief Executive Officer, ElevateBio, USA
  • Melissa K. Carpenter, Chief Scientific Officer, ElevateBio, USA

Interviewed by ISSCR Board Member Martin F. Pera, The Jackson Laboratories, USA l Stem Cell Reports Editor-in-Chief

ElevateBio is accelerating the rate of innovation in cell and gene therapy with a disruptive capital-efficient model.

13:55 EST

STEMCELL Technologies Executive Interview

  • Allen C. Eaves, Scientific Founder l Chief Executive Officer, STEMCELL Technologies, Canada

Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA

STEMCELL Technologies’ mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.

14:40 EST

Vertex Pharmaceuticals Executive Interview

  • Jeffrey Leiden, Executive Chairman, Vertex Pharmaceuticals, USA
  • Bastiano Sanna, Executive Vice President, Chief of Cell & Genetic Therapies & VCGT Site Head, Vertex Pharmaceuticals, USA

Interviewed by ISSCR Past President Douglas A. Melton, Scientific Founder, Semma Therapeutics, now Vertex Pharmaceuticals l Harvard University, USA

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

15:15 EST

FUTURECAST–STEMCELL Technologies, Inc.

  • Andrew Gaffney, Associate Director, iPSC and Differentiated Cells

Sponsored content

15:20 EST

Tenaya Therapeutics Executive Interview

  • Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, USA
  • Deepak Srivastava, Scientific Founder, Tenaya Therapeutics l Gladstone Institute/UCSF, USA l ISSCR Immediate Past President

Interviewed by ISSCR Board Member Charles E. Murry, Institute for Stem Cell and Regenerative Medicine, University of Washington/Sana Biotechnologies, USA

Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.

?

16:00 EST

Fate Therapeutics Executive Interview

  • Scott Wolchko, President and Chief Executive Officer, Fate Therapeutics, USA
  • Leonard I. Zon, Scientific Founder, Fate Therapeutics l Boston Children’s Hospital, USA l ISSCR Founder

Interviewed by ISSCR Board Member Takanori Takebe, Cincinnati Children’s Hospital Medical Center, USA/Tokyo Medical and Dental University and Yokohama City University, Japan

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

16:30 EST

Thought Leaders–Pivoting to the Future

  • Margaret A. Hamburg, Co-Chair, WHO Expert Advisory Group on Developing Global Standards for Governance and Oversight of Human Genome Editing and Global Standards for Governance and Oversight of Human Genome Editing l Former FDA Commissioner, USA
  • Rajiv Kaul, Sector Manager, Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund, USA
  • Andrew Plump, President, Research & Development, Takeda Pharmaceutical Company Limited and Member of the Board of Directors, USA
  • Jim Tananbaum, Founder and Chief Executive Officer, Foresite Capital, USA

Interviewed by ISSCR Immediate Past President Deepak Srivastava, Gladstone Institute/UCSF, USA

17:20 EST

Concluding Remarks

  • Christine Mummery, ISSCR President / Leiden University Medical Center, Netherlands

Friday, 8 January

Sponsored Industry Career Talks

12:00 -13:30 EST

Join us as participating companies discuss how the future of the stem cell field will shape the future of our careers – new opportunities, paths, and challenges. Attendees will hear from talent recruitment leaders and scientists who will discuss the transition from academia to industry, how to make it, and what to expect.

12:00 EST

Welcome

  • Keith Alm, ISSCR Chief Operating Officer, USA
  • Julia Tischler, ISSCR Membership Committee l École Polytechnique Fédérale de Lausanne, EPFL, Switzerland

12:05 EST

STEMCELL Technologies, Inc.

  • Christine Genge, Manager, Recruitment
  • Nina Quiskamp, Scientist

Question and Answer moderated by Julia Tischler, ISSCR Membership Committee l École Polytechnique Fédérale de Lausanne, EPFL, Switzerland

12:35 EST

BlueRock Therapeutics

>

  • Timsi Rao, Genome Sciences, Immunology
  • Stephany Sakharny, Senior Human Resources Manager

Question and Answer moderated by Julia Tischler, ISSCR Membership Committee l École Polytechnique Fédérale de Lausanne, EPFL, Switzerland

13:05 EST

ElevateBio

  • Cherylene Plewa, Vice President, Cellular Engineering
  • Austin Thiel, Director Stem Cell Biology

Question and Answer moderated by Julia Tischler, ISSCR Membership Committee l École Polytechnique Fédérale de Lausanne, EPFL, Switzerland

13:30 EST

Concluding Remarks

  • Keith Alm, ISSCR Chief Operating Officer, USA

###

Media are welcome to attend. Contact Kym Kilbourne at [email protected] for access.

VISION2030 is sponsored by STEMCELL Technologies, BlueRock Therapeutics, ElevateBio, Agilent, Catalent, BioLamina and Third Rock Ventures.

About the International Society for Stem Cell Research

With nearly 4,000 members from more than 60 countries, the International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health. Additional information about stem cell science is available at A Closer Look at Stem Cells, an initiative of the Society to inform the public about stem cell research and its potential to improve human health.

Media Contact
Kym Kilbourne
[email protected]

Leave A Reply

Your email address will not be published.